Published in Hum Gene Ther on June 01, 2008
Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther (2009) 1.71
Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther (2009) 1.64
Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. ILAR J (2009) 1.43
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood (2013) 1.36
Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther (2010) 1.24
Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. PLoS One (2012) 1.15
Animal models of hemophilia. Prog Mol Biol Transl Sci (2012) 1.04
Gene therapy for hemophilia. Front Biosci (Landmark Ed) (2015) 0.94
Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery. Hum Gene Ther Methods (2014) 0.91
Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia. J Genet Syndr Gene Ther (2012) 0.90
Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A. PLoS One (2014) 0.89
Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A. Gene Ther (2012) 0.86
Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery. Mol Ther Methods Clin Dev (2014) 0.83
Myosin7a deficiency results in reduced retinal activity which is improved by gene therapy. PLoS One (2013) 0.83
Advancements in gene transfer-based therapy for hemophilia A. Expert Rev Hematol (2009) 0.83
Systemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liver. Hum Gene Ther (2011) 0.82
Convenient and reproducible in vivo gene transfer to mouse parotid glands. Oral Dis (2011) 0.81
Engineering Factor Viii for Hemophilia Gene Therapy. J Genet Syndr Gene Ther (2011) 0.78
The impact of minimally oversized adeno-associated viral vectors encoding human factor VIII on vector potency in vivo. Mol Ther Methods Clin Dev (2016) 0.76
Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells. Biologics (2009) 0.76
Characteristics of Minimally Oversized Adeno-Associated Virus Vectors Encoding Human Factor VIII Generated Using Producer Cell Lines and Triple Transfection. Hum Gene Ther Methods (2017) 0.75
Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment. Gene Ther (2016) 0.75
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol (1983) 7.52
Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol (2004) 7.12
Gene therapy vectors based on adeno-associated virus type 1. J Virol (1999) 4.63
Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther (1996) 3.26
Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol (2000) 2.58
Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood (2003) 2.21
Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol (2005) 2.05
Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood (2006) 2.03
Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A (2000) 1.95
Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med (2000) 1.79
Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther (2001) 1.78
Generation and characterization of chimeric recombinant AAV vectors. Mol Ther (2003) 1.54
Self-complementary recombinant adeno-associated viral vectors: packaging capacity and the role of rep proteins in vector purity. Hum Gene Ther (2007) 1.44
Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood (2003) 1.15
Adeno-associated virus: a ubiquitous commensal of mammals. Hum Gene Ther (2005) 1.13
High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids. J Virol (2000) 1.12
A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J Thromb Haemost (2003) 1.11
Advances toward gene therapy for hemophilia at the millennium. Hum Gene Ther (1999) 1.11
Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis (1997) 1.09
Hydrodynamic delivery. Adv Genet (2005) 1.06
The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol Ther (2007) 1.03
Gene therapy for the hemophilias. Proc Natl Acad Sci U S A (1999) 1.01
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol (2002) 5.82
In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature (2011) 4.81
BrainNet Viewer: a network visualization tool for human brain connectomics. PLoS One (2013) 3.74
Uncovering intrinsic modular organization of spontaneous brain activity in humans. PLoS One (2009) 3.43
Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther (2008) 3.28
Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood (2003) 2.74
Diffusion tensor tractography reveals abnormal topological organization in structural cortical networks in Alzheimer's disease. J Neurosci (2010) 2.60
Disrupted brain connectivity networks in drug-naive, first-episode major depressive disorder. Biol Psychiatry (2011) 2.29
Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood (2005) 2.29
Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J Virol (2006) 2.07
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood (2007) 2.05
Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood (2006) 2.03
Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood (2008) 2.01
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood (2013) 1.98
Frequency-dependent changes in the amplitude of low-frequency fluctuations in amnestic mild cognitive impairment: a resting-state fMRI study. Neuroimage (2010) 1.86
Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther (2009) 1.71
Role of bone marrow transplantation for correcting hemophilia A in mice. Blood (2012) 1.67
AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models. PLoS One (2013) 1.62
Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood (2003) 1.62
Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med (2013) 1.56
Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther (2012) 1.55
Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest (2009) 1.54
Generation and characterization of chimeric recombinant AAV vectors. Mol Ther (2003) 1.54
Sex- and brain size-related small-world structural cortical networks in young adults: a DTI tractography study. Cereb Cortex (2010) 1.53
Hemisphere- and gender-related differences in small-world brain networks: a resting-state functional MRI study. Neuroimage (2010) 1.52
Aryl Hydrocarbon Receptor Activation Down-Regulates IL-7 and Reduces Inflammation in a Mouse Model of DSS-Induced Colitis. Dig Dis Sci (2015) 1.50
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood (2010) 1.50
Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther (2009) 1.49
Topologically convergent and divergent structural connectivity patterns between patients with remitted geriatric depression and amnestic mild cognitive impairment. J Neurosci (2012) 1.49
Cerebrospinal fluid apolipoprotein E concentration decreases after seizure. Seizure (2010) 1.45
De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med (2012) 1.40
Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex. J Biol Chem (2005) 1.39
Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther (2010) 1.38
Discriminative analysis of early Alzheimer's disease using multi-modal imaging and multi-level characterization with multi-classifier (M3). Neuroimage (2011) 1.37
Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. Mol Ther (2010) 1.35
Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood (2010) 1.32
Characterizing dynamic functional connectivity in the resting brain using variable parameter regression and Kalman filtering approaches. Neuroimage (2011) 1.32
Characterization of tissue tropism determinants of adeno-associated virus type 1. J Virol (2003) 1.29
FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res (2005) 1.29
Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol Ther (2009) 1.29
Statistical interaction in human genetics: how should we model it if we are looking for biological interaction? Nat Rev Genet (2010) 1.28
Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor. Cell (2002) 1.25
Effects of different correlation metrics and preprocessing factors on small-world brain functional networks: a resting-state functional MRI study. PLoS One (2012) 1.24
Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol Ther (2004) 1.24
Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther (2010) 1.24
Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J Immunol (2006) 1.21
Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J Virol (2002) 1.19
Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adeno-associated virus transduction. J Virol (2004) 1.17
Two-dimensional universal conductance fluctuations and the electron-phonon interaction of surface states in Bi2Te2Se microflakes. Sci Rep (2012) 1.17
Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood (2003) 1.15
Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J Virol Methods (2006) 1.15
Building a better dynasore: the dyngo compounds potently inhibit dynamin and endocytosis. Traffic (2013) 1.14
Two new lactones and one new aryl-8-oxa-bicyclo[3,2,1]oct-3-en-2-one from Descurainia sophia. Chem Pharm Bull (Tokyo) (2004) 1.14
Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proc Natl Acad Sci U S A (2005) 1.13
Loss of enteral nutrition in a mouse model results in intestinal epithelial barrier dysfunction. Ann N Y Acad Sci (2012) 1.13
Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol Ther (2012) 1.13
Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction. Proc Natl Acad Sci U S A (2007) 1.12
Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood (2013) 1.11
Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy. Curr Genomics (2009) 1.11
Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein. Clin Dev Immunol (2011) 1.11
Robust ZFN-mediated genome editing in adult hemophilic mice. Blood (2013) 1.11
Mapping QTL for multiple traits using Bayesian statistics. Genet Res (Camb) (2009) 1.10
Comparative study of SBP-box gene family in Arabidopsis and rice. Gene (2007) 1.09
Toward neurobiological characterization of functional homogeneity in the human cortex: regional variation, morphological association and functional covariance network organization. Brain Struct Funct (2014) 1.09
Abnormal small-world architecture of top-down control networks in obsessive-compulsive disorder. J Psychiatry Neurosci (2011) 1.07
Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma. Cancer Res (2013) 1.07
Toxicological characteristics of nanoparticulate anatase titanium dioxide in mice. Biomaterials (2009) 1.06
Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver. Mol Ther (2007) 1.06
Native molecular state of adeno-associated viral vectors revealed by single-molecule sequencing. Hum Gene Ther (2011) 1.05
Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein. Vaccine (2010) 1.05
Electron transport properties of atomic carbon nanowires between graphene electrodes. J Am Chem Soc (2010) 1.05
Development of robust organosilica membranes for reverse osmosis. Langmuir (2011) 1.05
Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J Antimicrob Chemother (2012) 1.05
Molecular evolution of the CPP-like gene family in plants: insights from comparative genomics of Arabidopsis and rice. J Mol Evol (2008) 1.04
Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties. J Virol (2005) 1.04
Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS One (2012) 1.04
Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis. J Cell Mol Med (2014) 1.03
Defining genetic determinants of the Metabolic Syndrome in the Framingham Heart Study using association and structural equation modeling methods. BMC Proc (2009) 1.03
The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol Ther (2007) 1.03
A bias-reducing strategy in profiling small RNAs using Solexa. RNA (2011) 1.02
Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice. Mol Ther (2010) 1.02
Polyfluoride anions, a matrix-isolation and quantum-chemical investigation. Inorg Chem (2010) 1.01
Dynamics of Th17 cells and their role in Schistosoma japonicum infection in C57BL/6 mice. PLoS Negl Trop Dis (2011) 1.01
Significance of the Rac signaling pathway in HCC cell motility: implications for a new therapeutic target. Carcinogenesis (2004) 1.01
miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin (Shanghai) (2012) 1.01
VlincRNAs controlled by retroviral elements are a hallmark of pluripotency and cancer. Genome Biol (2013) 1.00
Fractal analysis of ice crystals in frozen food. J Agric Food Chem (2002) 1.00
Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles. J Control Release (2008) 1.00
Transcriptome-wide survey of mouse CNS-derived cells reveals monoallelic expression within novel gene families. PLoS One (2012) 1.00
Enhanced factor VIII heavy chain for gene therapy of hemophilia A. Mol Ther (2009) 0.99